UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the ...

The British pharma giant plans to shell out ... despite existing approved products,” Luke Miels, chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab ... s Nucala for CRSwNP treatment" was originally created and published by Pharmaceutical Technology, a ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary ... Also, they introduced the Animal health products. In the year 1971, the company built the Research & development laboratory at Thane.